MedTrace Logo

Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung Cancer

NCT05387512 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-04-06

No results posted yet for this study

Summary

This retrospective real-world cohort study evaluated whether concomitant long-term beta-blocker exposure during routine clinical care was associated with clinical outcomes in patients with advanced NSCLC who received standard anti-PD-1/PD-L1 inhibitor therapy. Patients were categorized according to documented concomitant long-term beta-blocker exposure during the treatment course. Clinical outcomes, including progression-free survival, objective response rate, and overall survival, were compared between exposure groups. This was a non-interventional observational study; anti-PD-1/PD-L1 treatment and beta-blocker use were determined by routine clinical practice rather than by the study protocol.

Conditions

Interventions

DRUG

Anti-PD-1/PD-L1 Therapy (Standard of Care)

Standard anti-PD-1/PD-L1 inhibitor therapy administered as part of routine clinical care. Treatment regimen, schedule, and duration were determined by treating physicians according to standard practice and were not assigned by the study.

DRUG

Beta-blocker (Concomitant Exposure)

Documented concomitant long-term beta-blocker use during the anti-PD-1/PD-L1 treatment course as prescribed for routine clinical indications. Beta-blocker exposure was not assigned by the study protocol.

Sponsors & Collaborators

  • The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China

    collaborator OTHER

  • Affiliated Hospital of Nantong University

    lead OTHER

Principal Investigators

  • Zhiyuan Tang, Doctor · Affilication Hospital of Nantong University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05387512 on ClinicalTrials.gov